These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 20151319)

  • 1. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New development in intracrinology of breast carcinoma.
    Sasano H; Suzuki T; Nakata T; Moriya T
    Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
    Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
    Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
    Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
    Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid metabolism in breast cancer.
    Foster PA
    Minerva Endocrinol; 2008 Mar; 33(1):27-37. PubMed ID: 18277377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Wang L; Chan MS; Wing L; Yiu CC; Chow LW; Sasano H
    Horm Cancer; 2011 Feb; 2(1):73-81. PubMed ID: 21761341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy.
    Chan MS; Wang L; Chanplakorn N; Tamaki K; Ueno T; Toi M; Loo WT; Chow LW; Suzuki T; Sasano H
    Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S69-78. PubMed ID: 22309693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
    Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Yiu CC; Chanplakorn N; Chan MS; Loo WT; Chow LW; Toi M; Sasano H
    Anticancer Res; 2010 Sep; 30(9):3465-72. PubMed ID: 20944124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase.
    Sasano H; Nagasaki S; Miki Y; Suzuki T
    Ann N Y Acad Sci; 2009 Feb; 1155():76-9. PubMed ID: 19250194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
    Takei H; Kurosumi M; Yoshida T; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Oba H; Inoue K; Nagai S; Tabei T
    Breast Cancer; 2011 Apr; 18(2):85-91. PubMed ID: 21104350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
    Takagi K; Miki Y; Nagasaki S; Hirakawa H; Onodera Y; Akahira J; Ishida T; Watanabe M; Kimijima I; Hayashi S; Sasano H; Suzuki T
    Endocr Relat Cancer; 2010 Jun; 17(2):415-30. PubMed ID: 20228125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
    Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
    J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.